Slides
Page 1
Q2 FY-2025 Earnings Call
Page 2
Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2025 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport’s anticipation of continued growth in its services business and ongoing softness in product sales; Cryoport’s plans and expectations relating to its previously announced cost reduction and capital realignment strategies, including Cryoport’s plans to complete these adjustments by the year's end and Cryoport’s belief that these measures will lead to a return to positive adjusted EBITDA during 2025; Cryoport's expectations that the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue into the near future; and Cryoport's belief that it is strategically positioned to leverage the anticipated long-term growth in the Cell & Gene therapy market through Cryoport’s comprehensive and integrated supply chain solutions. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties include difficulties, delays or Cryoport's inability to successfully complete its planned cost reduction and capital realignment measures, which could reduce the benefits realized from such activities within the time periods currently anticipated. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this presentation speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this presentation. Forward Looking Statements © 2025 CRYOPORT, INC. 2
Page 3
3© 2025 CRYOPORT, INC. Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as: – Cell therapies – Gene therapies – Human and animal reproductive materials The recognized supply chain leader in supporting the C> market The leading manufacturer of cryogenic systems and accessories in the world One of the largest biorepositories in the U.S. Cryoport, Inc. (CYRX) operates as an operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry Cryoport – Trusted Partner to Life Sciences Companies
Page 4
4© 2025 CRYOPORT, INC. C> Supply Chain Leader Performance Global Platform (2) Source: Company Filings and materials Notes: (1) As of 6/30/2025 $45.5M +14% YoY growth Q2-2025 Revenue 18 Commercial Cell & Gene Therapies Supported Global Clients Base$8.7M +33% YoY growth Commercial Cell & Gene Therapies revenue $165 - $172M FY 2025 Revenue Guidance $426M Cash & Short-Term investments Key facilities in Americas, EMEA and APAC regions 690 Employees Cryoport – Q2 2025 Snapshot (all data from continuing operations) 728 Active Cell & Gene Therapy Clinical Trials Supported (2) Recent News Strategic Partnership with DHL Group and all cash divestiture of CRYOPDP specialty courier completed June 2025
Page 5
5© 2025 CRYOPORT, INC. Revenue by the Numbers
Page 6
6© 2025 CRYOPORT, INC. Driving Bottom-Line Improvement
Page 7
7© 2025 CRYOPORT, INC. LS Services Key Revenue Growth Drivers $3.5 $4.5 Q2 2024 Q2 2025 $6.5 $8.7 Q2 2024 Q2 2025 +28% YoY +33% YoY BioStorage/BioServices Revenue ($ in millions) Commercial CGT Revenue ($ in millions)
Page 8
8© 2025 CRYOPORT, INC. • 728 clinical trials (net) in aggregate • 82 Phase III trials in the Americas, EMEA, and APAC Clinical Trials Supported by Trial Phase as of 6/30/25Increased by 44 trials (net) over Q2-2024 Q2 2025: 82 Phase III Clinical Trials Supported by Cryoport Cryoport Systems’ Clinical Trial Support Source: Company materials cross-referenced to clinical trial information publicly available
Page 9
9© 2025 CRYOPORT, INC. Cryoport Systems’ Commercial Support 18 Total Products AKUUGO®
Page 10
10© 2025 CRYOPORT, INC. Notes: 1. Data as of 6/30/25 2. Combined totals of all Cryoport business units 3. Total shipments of Cryoport Systems from inception (all data exclude Cryopdp which was divested) Cryoport, Inc. is the Global Leader of Supply Chain Solutions for the Life Sciences The Life Sciences Trusted Provider of Integrated Temperature-controlled Supply Chain Solutions ~70% Of All Industry Clinical Trials Supported1 1,200+ Active Global Clients2 1M+ Shipments3 728 Active Cell & Gene Therapy Clinical Trials Supported1 18 Commercial Cell and Gene Therapies Supported1 15+ Locations in Americas, EMEA and APAC with 670+ people2
Page 11
11© 2025 CRYOPORT, INC. Cryoport’s Platform Solution Comprehensive Supply Chain Management
Page 12
12© 2025 CRYOPORT, INC. Cryoport’s Logistics Management Made Easy It’s as simple as a couple of clicks • Log into the Cryoportal® to create an order or select a prepopulated template • Carrier options, such as our Cryoshuttle®, integrators, and couriers or any combination to meet your specific shipment need are available • Once the order is placed, Cryoport Systems handles the rest and manages the entire process • All shipments legs including pickup, deliveries, and returns management are captured and assigned • Our 24/7/365 client service team provides updates through email notifications • Our Cryoportal® also provides automated updates to give you total peace of mind
Page 13
13© 2025 CRYOPORT, INC. Packaging Cryoport Systems’ Robust Shipper Fleet Cryoport Express® Cryoport Express® Standard Cryogenic Shipper Cryoport Express® Standard Cryogenic Combo Shipper CXCB1 Cryoport Express® Cryoport Express® Cryogenic ST1 Shipping System CXST1 -150° C or colder Cryoport Express® Cryogenic CB1 Shipping System CXCB1 -150° C or colder Cryoport Express® Cryogenic HV2 Shipping System CXHV2 -150° C or colder Cryoport Express® Sliderite® High Volume Pallet System CXSR2* -150° C or colder Cryoport Express® C3 Refrigerated Shipping System C3CH2124* 2°C to 8°C Cryoport Express® C3 Controlled Room Temperature Shipping System C3RT1124 15° C to 25° C Cryoport Express® CryoMax® Cryogenic Shipping System C1536PD 21 days at -150°C or colder Cryoport Elite® 28L Ultra Cold Shipping System ELUC128* -60° C to -80° C Cryoport Elite ® 56L Ultra Cold Shipping System ELUC156* -60° C to -80° C *Product offers both Advanced Therapy Shippers® (ATS) and General Purpose Shippers (GP). The ATS fleet is dedicated exclusively to cell and gene supply chain management and never contains non-human-based materials to eliminate cross-contamination. The GP fleet consists of shippers that allow for the use of both human and animal commodities. Cryoport Express® Cryogenic HV3 Shipping System CXHV3 -150° C or colder
Page 14
© 2024 CRYOPORT SYSTEMS CONFIDENTIAL | 14 Chain of Compliance® • Traceability of the equipment and processes used in managing the environmental control of the biomaterials o Serialization of the shipper and components o 100% shipper (re)qualification o Performance history of shipper and courier o Commodity history for every shipper o Deviation history of the shipper/courier o Transportation history of the shipper/courier o Maintenance/refurbishment history of the shipper o Calibration data and history of the data logger Note: General requirements for transportation of cells for therapeutic use Supports regulatory compliance requests from the EMEA/FDA and other regulatory agencies. Adheres to ISO 21973 Standard.
Page 15
15© 2025 CRYOPORT, INC. GMP Storage Regulatory & Consulting Services Biobanking Clinical Sample Management Logistics Management Services Drug Packaging & Labelling Kit Production Drug Recall, Return, & Destruction What Cryoport BioServices Offers:
Page 16
16© 2025 CRYOPORT, INC. We Store Offering GMP-compliant storage in state-of-the-art validated units at all temperatures We Fulfill Retrieving, labelling, and packaging your materials while keeping them at the required temperature We Dispose Offering regulatory-compliant drug recall, return, and disposal services to ensure full accountability of all products Cryoport BioServices Value Proposition Expert Support A Dedicated Program Manager Helping you plan and manage every stage of your project We Collect Using our specialized kitting, our experts collect your critical materials for manufacturing, testing, or clinical use We Protect Guaranteeing the safety of your materials through temperature monitoring, automated alerts, and back- up equipment We Transport Ensuring your shipment is transported compliantly and seamlessly at any temperature and to any destination We Comply Giving you full end-to-end traceability alongside our robust quality management systems with our Chain of Compliance®
Page 17
17© 2025 CRYOPORT, INC. IntegriCell Offering Cryopreservation Services & Process Development • Ready-to-use leukapheresis cryopreservation protocol • Technology transfer of client cryopreservation processes to IntegriCell teams and facilities • Customized cryopreservation process development services to meet client needs The Value We Offer • Optimization of cellular viability via cryopreservation within 24 hours post-collection • Standardization of cryopreservation protocols performed by experienced IntegriCell teams • Manufacturing slot utilization improved with the incorporation of cryopreservation • Global clinical trial coverage through our US and European footprint
Page 18
18© 2025 CRYOPORT, INC. IntegriCell Current Footprint Houston, USA CRYO Manufacturing Villers-le-Bouillet, Liège, BELGIUM CRYO Manufacturing • Cryopreservation Process Development • Cryopreservation Manufacturing for Clinical Grade/GMP compliant (1,000 units/year) • 19,078 sq. ft. (1,772.4 m2) • Cryopreservation Manufacturing for Clinical Grade/GMP compliant (1,000 units/year) • 5,500 sq. ft. (511 m2)
Page 19
19© 2025 CRYOPORT, INC. IntegriCell Logistics Flow
Page 20
© 2025 CRYOPORT, INC. 60 years of setting the standard for cryogenic storage Global leader in the provision of cryo- systems in the life sciences industry Headquarters: Ball Ground, GA 270 employees globally MVE Biological Solutions is the global leading manufacturer of cryogenic systems, providing cryogenic freezers, dewars, and related equipment used for cryogenic storage and transportation. • Three primary manufacturing locations: o Ball Ground, GA o New Prague, MN o Chengdu, China 20 MVE At A Glance The Leading Cryogenic Systems Manufacturer in the World
Page 21
21© 2025 CRYOPORT, INC. MVE’s Product Family CRYOGENIC FREEZERS Ball Ground, GA Bulk storage stainless-steel freezers in a range of sizes and configurations Basic bulk storage stainless-steel freezer for the breeder market CRYOGENIC DEWARS New Prague, MN Complete portfolio of aluminum dewars for sample storage, sample shipping, and LN2 storage CRYOGENIC DEWARS Chengdu, China Complete portfolio of aluminum dewars for sample storage, sample shipping, and LN2 storage
Page 22
CONFIDENTIAL | 22© 2025 MVE BIOLOGICAL SOLUTIONS® MVE is the only cryogenic storage manufacturer with FDA Registration, delivering cryogenic solutions that meet the highest regulatory standards, ensuring the safety of your valuable biological samples. MVE is FDA Registered
Page 23
CRYOGENE Houston Secure GMP compliant biorepository • Facility is above the 500-year flood plain and windows rated to 110 MPH winds • 8 generators supply emergency back up power to the entire facility, including HVAC • Natural disasters – in the past 20 years, 2 major hurricanes (wind and flooding events) and an unexpected freeze storm with no impact to the facility
Page 24
24© 2025 CRYOPORT, INC. CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center • 30,000 sq ft facility with exclusivity for biorepository services • Construction to begin Q2 2025 • Biological material transfers begin Q2 2026 • CRYOGENE will provide our services to biotech, research, and pharma companies in the region • 775-acre Speros Clinical Research Campus in Tampa, FL
Page 25
25© 2025 CRYOPORT, INC. A Unified Network Supporting the Life Sciences HQ
Page 26
26© 2025 CRYOPORT, INC. 26 Partnership and Transaction with DHL Group © 2025 CRYOPORT, INC.
Page 27
27© 2025 CRYOPORT, INC. • We share a common purpose: delivering life-preserving therapies and enabling the life sciences, improving lives around the world • CRYOPDP will integrate into the Supply Chain division of DHL and continue to work closely with Cryoport via a global agreement • Global Scale, Global Efficiency, and Global Flexibility Our New Partnership with DHL Group Brings together DHL’s global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions • Cryoport will maintain its relationship with CRYOPDP as a part of DHL Group • Industry-leading expertise in providing specialized solutions in the fast-growing specialty pharma market segment • Acquisition enhances DHL’s capabilities in specialty pharma logistics • Supports Group’s 2030 strategy to become a leader in life science and healthcare logistics
Page 28
28© 2025 CRYOPORT, INC. DHL in Figures – LSH Market DHL Life Sciences & Healthcare Global Network Global network with >580 locations handling LSH shipments >11,000 LSH trained colleagues €2bn investment to 2030 Number of Operations 588 GDP Operations 257 (For DGF – GXP certification) Total Temp-Controlled Storage (sq. m) 2,794K (Express storage capacity n/a)
Page 29
29© 2025 CRYOPORT, INC. Q2 2025 Revenue
Page 30
30© 2025 CRYOPORT, INC. Q2 Balance Sheet